凯赛生物(688065) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 reached ¥775,769,935.75, representing a 13.33% increase compared to ¥684,521,536.95 in the same period last year[4] - Net profit attributable to shareholders was ¥136,950,113.57, a 30.11% increase from ¥105,258,699.94 year-on-year[4] - Net profit for Q1 2025 was CNY 124,318,691.92, compared to CNY 106,857,611.48 in Q1 2024, representing an increase of 16.25%[19] - The operating profit for Q1 2025 was CNY 161,685,700.77, up from CNY 123,463,826.25 in Q1 2024, indicating a growth of 30.93%[19] - Total revenue for Q1 2025 reached CNY 775,769,935.75, an increase of 13.38% compared to CNY 684,521,536.95 in Q1 2024[18] - Earnings per share for Q1 2025 were CNY 0.23, compared to CNY 0.18 in Q1 2024, marking a 27.78% increase[20] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 59.36% to ¥87,489,386.91, down from ¥215,276,527.96 in the previous year[4] - Cash received from sales and services in Q1 2025 was CNY 701,043,331.96, an increase from CNY 649,158,049.17 in Q1 2024, reflecting a growth of 7.99%[23] - Total cash outflow from operating activities was $657,274,979.57, an increase from $537,266,390.20 in the previous period[24] - Cash and cash equivalents at the end of the period totaled $10,635,851,218.02, up from $4,795,218,006.40 at the end of the previous period[25] - The net increase in cash and cash equivalents was $5,449,886,504.90, contrasting with a decrease of $218,561,556.52 in the prior period[25] Assets and Liabilities - Total assets increased by 29.80% to ¥24,689,868,403.18 from ¥19,021,477,349.64 at the end of the previous year[5] - The company's total liabilities decreased to RMB 3,161,806,107.54 from RMB 3,531,118,757.92, indicating a reduction of about 10.5%[16] - The total current liabilities decreased to RMB 2,538,495,884.89 from RMB 2,917,855,546.03, a reduction of about 13.0%[16] - The company's cash and cash equivalents increased significantly to RMB 10,797,271,252.93 from RMB 5,346,793,890.23, representing an increase of about 102.3%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,060[8] - The company's equity attributable to shareholders increased by 52.64% to ¥17,563,815,224.81 from ¥11,507,005,495.25[5] - Total equity attributable to shareholders increased from CNY 11,507,005,495.25 to CNY 17,563,815,224.81, a growth of 52.73%[17] Research and Development - R&D investment totaled ¥60,550,596.03, up 35.21% from ¥44,784,258.67, accounting for 7.81% of revenue[5] - Research and development expenses for Q1 2025 were CNY 60,550,596.03, compared to CNY 44,784,258.67 in Q1 2024, representing an increase of 35.25%[19] Other Financial Metrics - The weighted average return on equity rose to 1.18%, an increase of 0.24 percentage points from 0.94%[4] - The basic and diluted earnings per share were both ¥0.23, reflecting a 27.78% increase from ¥0.18[4] - Non-recurring gains and losses amounted to ¥1,587,608.51 for the period[6] - Other comprehensive income for Q1 2025 was CNY 3,862,477.80, compared to a loss of CNY 2,075,953.82 in Q1 2024, indicating a significant turnaround[20]